AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Analysts at Evercore ISI previously forecast that Vyalev could be one of AbbVie’s “biggest new product launches over the next year or two,” projecting the product could generate more than $2 ...

The creation of AbbVie In 2011 ... of brain applications is high. The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting ...

AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. Boosted by its new product launches, AbbVie expects to return to robust revenue growth in 2025.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus ...

Biotherapeutic firm EvolveImmune Therapeutics gets $65 million upfront and potentially $1.4 billion more if drugmaker AbbVie licenses its T-cell therapy.

AbbVie (NYSE:ABBV) will report third-quarter results next week and I expect to see a continuation of trends from the first half of the year with top and bottom-line beats and an improved full-year ...